Immuno-oncology Drugs Market, Immuno-oncology Drugs Market PDF Format CMI22 | Page 2

around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people sufering from cancer worldwide. There are many immuno-oncology drugs in the pipeline such as CAR-T cell therapy ofered by Juno Therapeutics, Inc. and Kite Pharma. Immuno-oncology drugs has proven clinical profle and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost growth of the immuno-oncology drugs market. Request Customization: https://www.coherentmarketinsights.com/insight/request-customization/1271 Market Players Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hofmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfzer Inc., Sanof S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: [phone] Email: [email protected] .